Micro-D3

Quick links to important sections

Micro-D3

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Micro-D3

What is Micro-D3?

Micro-D3 is a pharmacological formulation of cholecalciferol, more commonly known as Vitamin D3. It is designed to address vitamin D deficiency and maintain adequate serum levels of this essential fat-soluble nutrient.

Composition and Mechanism

The active ingredient, cholecalciferol, is the same form of Vitamin D that the human body naturally synthesizes in the skin when exposed to ultraviolet B (UVB) sunlight. Once ingested, Micro-D3 undergoes two metabolic hydroxylations to become biologically active:

  1. First Hydroxylation: Occurs in the liver, converting cholecalciferol into calcifediol.
  2. Second Hydroxylation: Occurs primarily in the kidneys, converting calcifediol into calcitriol, the active hormonal form.

Biological Role

Micro-D3 plays a fundamental role in systemic mineral homeostasis. Its primary functions include:

  • Calcium and Phosphate Absorption: It enhances the efficiency of the small intestine to absorb dietary calcium and phosphorus, which are critical for bone mineralization.
  • Bone Health: It supports the continuous remodeling of bone tissue and helps maintain the structural integrity of the skeletal system.
  • Cellular Function: Beyond bone health, Vitamin D receptors are found in various tissues throughout the body, where the nutrient contributes to normal cellular growth and neuromuscular function.

Clinical Applications

Micro-D3 is utilized in clinical settings to manage conditions characterized by insufficient vitamin D levels. This includes the prevention and management of bone density loss and the support of metabolic processes that rely on stable calcium levels. It is often used as a long-term nutritional support for individuals with limited sunlight exposure or those with malabsorption syndromes.

Regulatory References

  1. Cholecalciferol - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Micro-D3?

Possible Side Effects and Safety Information

The official safety profile of Micro-D3 (Cholecalciferol) is primarily defined by the risks associated with excessive intake, which can lead to elevated mineral levels, specifically high calcium in the blood (hypercalcaemia). This framework is derived from regulatory classifications used by government health authorities.


Adverse Reactions and Regulatory Frequencies

The most frequently documented adverse effects relate to mineral metabolism. Reactions are formally classified by frequency in official documents:

System Organ Class Frequency Classification Adverse Reaction
Metabolism and Nutrition Disorders Uncommon (Affecting < 1 in 100 people) Hypercalcaemia, Hypercalciuria (high urine calcium)
Skin and Subcutaneous Disorders Rare (Affecting < 1 in 1,000 people) Pruritus (itching), Rash, Urticaria (hives)
Immune System Disorders Not Known Hypersensitivity reactions (e.g., Angioedema)

Serious Safety Considerations and Restrictions

The primary serious safety concern is the potential for Hypervitaminosis D, which can result in persistent, severe hypercalcaemia. Chronic or extreme hypercalcaemia is documented in regulatory sources as a risk for serious complications, including the formation of nephrocalcinosis (kidney calcification) and nephrolithiasis (kidney stones), as well as cardiac arrhythmias.

The medicine is formally contraindicated and must not be used in individuals with pre-existing conditions such as Hypervitaminosis D, Hypercalcaemia, Nephrolithiasis, or Severe Renal Impairment. Caution is also advised in populations such as those with Sarcoidosis, due to the risk of altered vitamin metabolism, requiring closer observation of calcium levels as specified in official labeling.

Overdose and Emergency Response

Micro-D3 overdose is characterized by the development of Hypercalcemia (high calcium levels), which drives the documented adverse manifestations. Clinical signs listed in regulatory labeling include systemic symptoms such as loss of appetite and weakness, alongside gastrointestinal effects like nausea and vomiting. Overdose may also present with changes in fluid balance, including increased thirst (polydipsia) and increased urination (polyuria), as well as confusion.

Regulatory documents classify the risk as potentially severe, noting that untreated Hypercalcemia may lead to life-threatening outcomes, including heart arrhythmias, seizures, and permanent kidney failure. If an overdose is suspected, the patient must stop the medication immediately and seek medical attention. Treatment is symptomatic and supportive, requiring frequent monitoring of blood calcium determinations. Emergency services must be contacted immediately if collapse, seizure, or trouble breathing occurs. The official profile notes an elevated risk of toxicity for patients with liver disease or chronic kidney failure.

Therapeutic Uses of Micro-D3

What Micro-D3 Treats: Main Uses and Benefits

Micro-D3 (Cholecalciferol) is relevant within therapeutic areas involving systemic imbalance, which provides supportive relief across domains where additional symptomatic support is needed.

Micro-D3 is commonly used to help with preventing or treating Vitamin D deficiency and its associated bone diseases. Its therapeutic benefit is applicable within clinical settings that involve systemic imbalance. The medication is commonly used to manage clinical situations involving Vitamin D deficiency and insufficiency, along with related disorders such as Rickets in children, Osteomalacia in adults, and the long-term management of Osteoporosis.

In these scenarios, the medication may assist with managing symptoms related to physical discomfort and helps ease symptom clusters that may become intense or disruptive, including diffuse bone and muscle pain and proximal muscle weakness. The use of Micro-D3 supports muscle function and stability, which assists with maintaining functional stability and contributes to improved comfort during symptomatic periods.

Quick Fact: Relief for Musculoskeletal Symptoms
Common Scenarios Used when dietary intake is inadequate or due to limited sun exposure; relevant for patients with malabsorption issues.
Symptom Focus Helps manage diffuse bone and muscle pain and weakness related to deficiency.
Core Benefit Contributes to easing the overall symptom load and supports structural health, which may assist with maintaining stability in conditions where functional stability becomes affected.

Regulatory References

  1. Cholecalciferol (Vitamin D3): MedlinePlus Drug Information

Eligibility and Restrictions for Use

Micro-D3 (Cholecalciferol) eligibility is strictly defined by official population rules documented in government regulatory labeling. The medicine must not be used in populations with specific metabolic conditions or severe organ impairment, which are formally categorized as contraindicated.

Eligibility Status Key Restriction or Condition
Contraindicated Hypervitaminosis D, Hypercalcaemia, Hypercalciuria, Severe Renal Impairment, and Nephrolithiasis (kidney stones).
Use with Caution Sarcoidosis or Mild to Moderate Renal Impairment due to the need for close monitoring of serum calcium levels. Conditional use also applies to patients with Malabsorption Syndrome.

Age-related rules establish general eligibility for adults and older adults. However, use in children under 12 years is not recommended for specific high-strength solid forms, as safety and efficacy data may not be established for these age groups. For pregnancy and lactation, use is permitted at recommended doses to treat maternal deficiency, but high-dose treatment is strictly contraindicated. Hepatic impairment requires no specific dose adjustment or limitation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details the official interaction profile for Micro-D3 (Cholecalciferol) as documented in government regulatory sources, focusing strictly on required administration constraints and documented interaction outcomes.

Interaction Scope and Classification

Feature Official Regulatory Classification
Interacting Categories Anticonvulsants (e.g., Phenytoin), Bile Acid Sequestrants (e.g., Cholestyramine), Lipase Inhibitors (e.g., Orlistat), Thiazide Diuretics, and Cardiac Glycosides (e.g., Digoxin).
Mechanistic Basis Impaired Absorption (Pharmacokinetic), Increased Catabolism (Enzyme-mediated), and Additive Effect on Calcium Regulation (Pharmacodynamic).
Timing Requirements Administration timing must be separated by a minimum of two hours for agents that interfere with absorption, such as Bile Acid Sequestrants.
Population Notes Increased risk of interaction-related Hypercalcemia is noted for individuals with compromised renal function and Geriatric populations.

Official Interaction Statements

  • A Pharmacokinetic Interaction is documented where specific Anticonvulsants increase the catabolism of Micro-D3, resulting in officially recorded reduced systemic exposure.
  • Co-administration with Thiazide Diuretics or high-dose Calcium Supplements is a documented Pharmacodynamic Interaction due to an additive effect on mineral homeostasis, elevating the risk of Hypercalcemia.
  • The Micro-D3 label establishes an interaction restriction mandating that it must not be combined with other Vitamin D Analogs (e.g., Calcipotriene).

The official regulatory profile is structured by substances that reduce Cholecalciferol exposure through absorption or metabolic interference, and those that introduce an additive hypercalcemia risk through pharmacodynamic effects. These established interaction patterns define mandatory restrictions on co-administration and requirements for the timing of drug intake.

Mechanism of Action

Micro-D3, a synthetic analog of 1,25-dihydroxyvitamin D, functions as an agonist for the nuclear Vitamin D Receptor (VDR). Upon binding to VDR, the complex subsequently heterodimerizes with the Retinoid X Receptor (RXR). This VDR–RXR heterodimer translocates to the cell nucleus and recognizes Vitamin D Response Elements (VDREs) within the promoter regions of target genes. The binding event modulates the transcription rate of these genes. This transcriptional regulation controls the expression of proteins integral to calcium and phosphate transport, including epithelial calcium channel TRPV6 and the calcium-binding protein calbindin-D28k. The resultant cascade of modulated protein expression alters intestinal calcium absorption and renal phosphate reabsorption. This process further affects the circulating concentrations of key regulatory hormones, specifically Parathyroid Hormone (PTH) and Fibroblast Growth Factor 23 (FGF23). This overall pharmacodynamic action establishes a modulated state of calcium and phosphate homeostasis across relevant organ systems.

Dosage and Administration Information

How to Use Micro-D3: Official Administration Principles

Micro-D3 (Cholecalciferol) administration is governed by official instructions focused on dosage regimen and specific intake conditions. The sole approved route of administration is oral (PO), encompassing dosage forms such as the soft-gel capsule, tablet, and oral solution.


Official Dosing and Frequency

Administration follows a biphasic pattern established in regulatory labeling, dividing use into two main stages based on clinical status. The Induction Phase for treating established deficiency typically employs high-dose regimens, such as 50,000 IU once weekly for 6–8 weeks, or a 1,000 IU to 6,000 IU once daily dose for up to three months. Following correction, use transitions to a Maintenance Phase, with standard daily doses generally ranging from 600 IU to 2,000 IU.


Administration Requirements

Administration must follow specific conditions to ensure proper use:

  • Timing: Oral forms are preferably taken with the main meal of the day to optimize the absorption of the fat-soluble Cholecalciferol.
  • Preparation: Liquid oral solutions require the use of the provided measuring device (dropper or syringe) for accurate dosing. Chewable forms must be chewed or crushed completely before swallowing.
  • Supervision: The initial high-dose regimen for deficiency treatment is typically initiated under medical supervision.

Official labels also outline specific constraints for vulnerable populations: use in patients with severe renal impairment is generally not recommended, while those with hepatic impairment require no routine dose adjustment.

Recent Clinical Evidence

Research evidence / Overview of Studies for Micro-D3

Evidence for Use in Correcting Vitamin D Status

Micro-D3 (Cholecalciferol) was studied for its role in settings involving low Vitamin D status, known as deficiency or insufficiency. The research exploring this area primarily consists of short-term and long-term Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies examined shifts in serum 25(OH)D concentration, which is the primary blood marker for Vitamin D status, as well as the regulation of minerals like calcium.

Studies reported measurements of measurable change in the serum 25(OH)D concentration biomarker following administration in observed populations. The research was evaluated in diverse demographic groups. However, the scientific community is still emerging toward a full consensus on the exact optimal target level for this biomarker.


Evidence for Use in Adjunctive Osteoporosis Management

Micro-D3 was evaluated in large-scale, multi-year RCTs and Meta-analyses concerning the management of Osteoporosis, often alongside other treatments. These studies examined long-term endpoints such as the rate of fracture incidence and changes in Bone Mineral Density (BMD) over several years.

Findings were mixed when pooling data from different research, particularly when Micro-D3 was studied for fracture incidence without simultaneous calcium use. Some large trials reported patterns observed in the studies but did not find a strong, consistent signal of change in fracture rates. The evidence quality varies across studies and is broadly described as moderate.


What Remains Uncertain and Areas of Research Gap

A key area of uncertainty is the lack of scientific consensus regarding the most beneficial long-term target level for the Vitamin D biomarker in healthy adults. Evidence is limited for long-term effects on populations who are not severely deficient, and the results apply only to the populations studied within the research parameters. This highlights what is known — and what is still uncertain — about Micro-D3.

Key Studies & References

  1. Vitamin D and muscle function: A systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Micro-D3 (FAQ)

Q: What is the main difference between Micro-D3 and a standard vitamin D supplement?

A: Micro-D3 is the specific name for Cholecalciferol (Vitamin D3), which is one of the two main forms of vitamin D available in supplements; the other is D2 (Ergocalciferol). Official information states that Vitamin D3 is the same naturally occurring form that your body produces when skin is exposed to sunlight.

Q: Is Micro-D3 a steroid or a hormone?

A: Micro-D3 is technically classified as an inert, fat-soluble vitamin that is chemically a secosteroid. However, official guidance notes that once your body activates it, its final form (Calcitriol) acts as a hormone by binding to nuclear receptors that regulate gene expression.

Q: How does Micro-D3 affect calcium levels in the body?

A: The mechanism of action for Micro-D3 involves modulating the body’s ability to absorb calcium from the intestine and influencing phosphate reabsorption in the kidneys. This process helps to maintain a regulated balance of calcium and phosphate across relevant organ systems, a state known as homeostasis.

Q: How quickly does Micro-D3 start working in the body?

A: The drug must go through two chemical conversion steps in the liver and kidneys to become fully active. The main circulating form of the drug has a biological half-life of approximately 15 days. This means the full process takes time before blood levels reach a stable therapeutic state.

Q: What are the general expectations about the duration of its effects after stopping Micro-D3?

A: Studies indicate that the main storage form of the drug, known as 25(OH)D, has a circulating half-life of approximately 15 days. This half-life reflects how long the compound remains systematically present in the body after the last administration.

Q: Does Micro-D3 help with muscle weakness, or is that a separate issue?

A: Official guidance notes that Vitamin D deficiency is often linked to symptoms such as muscle pain and weakness. Research has examined the role of the drug in supporting muscle function by helping maintain adequate calcium levels, which are essential for muscle contraction.

Q: Is Micro-D3 known to affect mood or energy levels?

A: Deficiency in Vitamin D is sometimes associated with symptoms such as fatigue and depressive symptoms. Conversely, official safety information indicates that signs of excessive intake (toxicity) may include subtle mental or mood changes and feelings of unusual tiredness.

Q: Is Micro-D3 used for conditions other than bone health?

A: Yes, official documents describe Micro-D3's use for the prevention and treatment of Vitamin D deficiencies and insufficiencies. Research has also examined its role in supporting overall immune system function and muscle health.

Q: Is it true that Micro-D3 can affect phosphorus levels?

A: Yes, according to the official mechanism of action, the drug regulates the reabsorption of calcium and phosphate in the kidneys. This process helps maintain the body's mineral homeostasis, which includes managing circulating phosphorus levels.

Q: Can Micro-D3 be taken with my morning coffee or a meal?

A: Official administration instructions state that Micro-D3 is preferably taken with the main meal of the day. This is due to the compound being fat-soluble, and its absorption is generally enhanced when taken with food, as noted in regulatory sources.

Q: Does using Micro-D3 require any special diet changes?

A: Official guidance indicates that dietary intake of foods containing natural or added calcium, phosphate, and vitamin D may need adjustment. The necessity of specific dietary guidance is related to managing the risk of mineral imbalance.

Q: Are there any specific food items to avoid when using Micro-D3?

A: Regulatory information indicates that foods high in calcium, phosphate, or vitamin D may require adjustment to prevent toxicity. Some sources also note that consumption of grapefruit may alter the blood levels of the drug.

Q: Is it okay to take other vitamin or mineral supplements while using Micro-D3?

A: Regulatory sources establish a restriction against combining Micro-D3 with other Vitamin D Analogs. The concurrent use of high-dose calcium or phosphate supplements is associated with an additive effect that increases the risk of hypercalcaemia (high blood calcium).

Q: Can Micro-D3 interact with antacids or iron supplements?

A: Iron supplements and Vitamin D3 generally do not interfere with each other's absorption. Regulatory principles for absorption, however, may necessitate specific timing, such as taking Micro-D3 with a meal.

Q: What are the requirements for storing Micro-D3 properly?

A: Official requirements mandate that the drug be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The medication must also be stored protected from light and moisture to maintain its expected strength.

Q: Does Micro-D3 lose its strength over time?

A: Official stability studies define a shelf life (often 24 months) for the drug product when stored according to precautions. This implies the strength is expected to be maintained until the designated expiration date.

Q: What is the purpose of the different strengths or forms of Micro-D3?

A: Micro-D3 is offered in various strengths (e.g., high-dose vs. low-dose) and different forms (e.g., liquid, capsule, tablet). This variety allows for the individualization of dosing based on the severity of the patient's Vitamin D deficiency or insufficiency.

Q: What are the descriptive usage conditions for Micro-D3?

A: Usage conditions include the specified oral route of administration, the recommendation to take the drug with the main meal of the day, and the official requirement for liquid forms is the use of the provided measuring device to ensure dosage accuracy.

Q: If I miss a dose of Micro-D3, what is the usual guidance?

A: Official guidance for managing a missed dose in similar weekly regimens is available in the product's official labeling, and this guidance addresses the scenario of returning to the original schedule.

Q: What happens if someone accidentally takes too much Micro-D3?

A: The signs of taking too much (overdosage or Hypervitaminosis D) can include vague aches, headache, loss of appetite, nausea, vomiting, increased thirst (polydipsia), and frequent urination (polyuria). The onset of overdosage symptoms represents a serious safety consideration that is documented in regulatory sources.

Q: What are the official warnings about high levels of calcium while using Micro-D3?

A: Official warnings state that high blood calcium (hypercalcaemia) is the primary serious concern. Sustained, severe hypercalcaemia poses a risk for serious complications, including the formation of kidney stones, kidney calcification, and cardiac arrhythmias.

Q: Why do official documents mention monitoring blood tests while on Micro-D3?

A: Official guidelines advise monitoring serum 25( OH) D, calcium, and phosphorus levels periodically. This monitoring is advised to assess Vitamin D status correction and, critically, to ensure that mineral levels remain within the desired range to prevent potential toxicity.

Q: Why are some people advised to take Micro-D3 only under close medical supervision?

A: Official labeling establishes that for individuals with certain pre-existing conditions, such as kidney disease or specific calcium disorders, use is restricted to be only under the supervision of a physician.

Q: What kind of eligibility criteria are described in official documents for Micro-D3 use?

A: Eligibility criteria are described primarily through the formal contraindications that restrict use. These include conditions like pre-existing high blood calcium (Hypercalcaemia), high levels of vitamin D (Hypervitaminosis D), or conditions affecting the kidneys like kidney stones or severe renal impairment.

Q: If I have a history of kidney stones, is Micro-D3 appropriate for me?

A: The official safety profile states that the presence of existing nephrolithiasis (kidney stones) is a formal contraindication. Regulatory sources restrict the use of the drug when this condition is present.

Q: I have kidney issues—does that change whether I can use Micro-D3?

A: Yes, Severe Renal Impairment is a formal contraindication. For individuals with less severe kidney disease, regulatory information requires that the drug be used only under medical supervision, due to the kidney’s role in one of the drug's essential activation steps.

Q: Why is Micro-D3 specifically mentioned in guidelines for certain types of kidney disease?

A: The drug must undergo a key biotransformation process in the kidneys to become fully active. Since renal impairment can hinder this activation and alter the drug’s therapeutic effect, regulatory guidelines require careful monitoring and sometimes dose adjustment in this population.

Q: Can people with liver problems use Micro-D3?

A: The drug is hydroxylated (processed) in the liver as the first step toward becoming active. Regulatory information notes that hepatic impairment can alter the drug's metabolism. As such, some high-dose products are not recommended for individuals with pre-existing liver disease.

Q: How does the body process and eliminate Micro-D3?

A: The drug is processed in a two-step activation sequence involving the liver and the kidneys, which is essential for creating the active form. Micro-D3 is then primarily eliminated from the body by bile acid secretions into the intestine, followed by excretion in the feces.

Q: Is Micro-D3 generally considered appropriate for elderly patients?

A: Regulatory information notes that dose selection for elderly patients should be cautious, often starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function in this population.

Q: Can Micro-D3 be used by children, and if so, for what reasons?

A: Yes, the drug is used in children to prevent and treat Vitamin D deficiencies, which manifest as rickets. Official guidance specifies that pediatric doses must be individualized based on the child's age and specific needs, reflecting the need for medical supervision in this population.

Q: What is the information on using Micro-D3 during pregnancy or breastfeeding?

A: Official labeling advises that the use of Micro-D3 in amounts exceeding the recommended dietary allowance during normal pregnancy should be avoided. The drug is known to pass into breast milk, and official labeling requires a careful assessment of the potential benefit versus any potential hazards when considering use during pregnancy or breastfeeding.

Q: What does the research say about Micro-D3 and immune system function?

A: Research has examined the role of Vitamin D in modulating the immune system and supporting anti-inflammatory responses. Research describes its role in the modulation of the immune system and its influence on the activation of immune cells.

How should Micro-D3 be stored and disposed of?

Storage Conditions

Micro-D3 (cholecalciferol) preparations must be stored according to regulatory labeling to ensure stability. Official requirements mandate storage at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with protection from excessive heat and freezing. The medication must be kept in its original container, tightly closed, and protected from light and moisture.

Child Safety and Handling

All Micro-D3 products must be stored out of the sight and reach of children. For some liquid solutions, specific stability rules require the unused portion to be discarded after 3 months of first opening.

Disposal Instructions

Unused or expired Micro-D3 should be disposed of in accordance with local requirements. The preferred method is using a drug take-back program or event. If a take-back option is unavailable, the product should be mixed with an undesirable substance (such as coffee grounds or kitty litter) and sealed in a bag before placing it in the household trash, while avoiding disposal via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Micro-D3 found in:

A-Z Index: